AbbVie Lifted Its 2026 Outlook After Another Strong Quarter
AbbVie reported Q3 revenue of $67.8B, slightly above estimates, driven by 16% growth in immunology sales. CEO Robert Michael highlighted pipeline milestones. Q4 EPS guidance of $3.83-$3.87 is below consensus. According to the company, the stock has gained 28.91% year-to-date.
How this was made
The 30-second read
Why it matters
The guidance miss is likely to weigh on ABBV's stock in the short term, though underlying product momentum could support a rebound.
Market read
Key earnings and guidance update for a large‑cap pharma stock.
What to watch
Strong growth in Skyrizi, Rinvoq, and neuroscience may offset the guidance shortfall over the longer term.
Background
AbbVie posted a solid quarter with 16% immunology growth, but its EPS outlook fell short of expectations.
Ticker impact
AbbVie reported Q4 results and lowered its 2026 EPS guidance to $3.83‑$3.87, below the $3.93 consensus.
downward pressure as investors price in weaker earnings outlook
Guidance below consensus typically leads to a near‑term price decline for large‑cap pharma stocks.
Market effects
Potential drag on the broader pharma sector as peers may be re‑rated.
U.S. market may see modest weakness in healthcare indices.
Limited to U.S. and global pharma investors.
Counterpoint
If the market overreacts to the guidance miss, a bounce could occur on the strength of rising immunology sales.
Key entities
- companyAbbVie
U.S. pharmaceutical company
